glp-1 and dpp-4 inhibitors Series Part 1: Utilization drives decline in inhibitors, increase in SGLT2s among competitive drug classes Design principles of long-acting DPP-4

Now, in an August 15, 2025, memorandum, Judge Karen M

Do not use on damaged or broken skin

Rubin MR, Cosman F, Lindsay R, Bilezikian JP

Wegovy tablets and injections are FDA-approved in adults for: weight loss and weight management in adults with obesity or adults who are overweight and have a weight-related medical problem (e.g., blood pressure, type 2 diabetes, or high cholesterol) reducing major cardiovascular event risks (such as heart attack, stroke, or death) in adults with established CV disease and either obesity or overweight Wegovy injection is also FDA-approved for: weight loss and weight management patients with obesity who are 12 years and older non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), this is an accelerated approval